Gene therapy breakthrough? new trial targets rare brain disorder FOXG1
NCT ID NCT07293546
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-stage trial tests a new gene therapy called FRF-001 for FOXG1 syndrome, a rare genetic disorder that affects brain development. The therapy is given as a single injection into the brain's fluid spaces. The study will include 12 children and adults and will check for safety and whether it helps improve motor skills like sitting, crawling, or walking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FRF-001 (a gene therapy using a harmless virus to deliver a working FOXG1 gene into the brain)
- What this could lead to
- If successful, this could point toward a treatment that improves motor skills and quality of life for people with FOXG1 syndrome.
- What could go wrong
- This is a very early, first-in-human trial with only 12 participants. The gene therapy may not work, could cause side effects, and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOXG1 SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital (Baylor College of Medicine)
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.